Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) is a clinical-stage biopharmaceutical company dedicated to advancing innovative anti-infective therapies for orphan indications. Utilizing proprietary lipid-crystal nano-particle cochleate technology, Matinas BioPharma aims to enhance the safety, tolerability, and oral bioavailability of existing drugs, thereby reducing their toxicity and improving patient outcomes.
The company's leading drug candidate, MAT2203, is an orally-administered, encochleated formulation of amphotericin B, a broad-spectrum fungicidal agent. Currently in Phase 2 clinical trials, MAT2203 seeks to offer a less toxic and more effective oral treatment for severe fungal infections.
Another promising candidate is MAT2501, an orally-administered, encochleated formulation of amikacin. Amikacin is a broad-spectrum aminoglycoside antibiotic agent effective against acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections. MAT2501 is currently in Phase 1 clinical trials, following an open Investigational New Drug (IND) application.
Matinas BioPharma's innovative approach positions the company at the forefront of developing next-generation anti-infective therapies. The firm's pipeline also includes other drug candidates that aim to address unmet medical needs in infectious disease treatment. By leveraging its nano-encapsulation technology, Matinas BioPharma is committed to creating safer and more effective treatments for patients.
Latest News:
- A photo accompanying this announcement is available
- Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden, and improvement in lung infection.
- Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) reported financial results for Q1 2024, with $10 million financing to fund development programs. Discussions continue to partner for Phase 3 trial of oral MAT2203, showing promising results in fungal infections. LNC platform expansion into inflammation and oncology is supported by positive data. Cash position is strong, with $8.1 million as of March 31, 2024, sufficient to fund operations into Q2 2025.
Matinas BioPharma Holdings, Inc. announces that Chief Medical Officer, James J. Ferguson, will present two abstracts at the ASGCT Annual Meeting on the use of its lipid nanocrystal (LNC) platform for small oligonucleotide delivery. The presentations will focus on the uptake and targeted delivery of small oligonucleotides in innate immune cells and the successful in vivo oral delivery of therapeutic anti-inflammatory mRNA-targeted oligonucleotides using the LNC platform.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) will report first quarter 2024 financial results on May 9, 2024. The company, known for its lipid nanocrystal platform technology, will discuss financials and business updates in a webcast. Investors can participate in the conference call or webcast to gain insights into the company's performance.
Matinas BioPharma's oral formulation MAT2203, a less invasive treatment for mucormycosis, shows efficacy in treating fungal infections in mice. The study demonstrates prolonged survival, reduced fungal burden, and improved lung infection.
The promising results suggest that MAT2203 could be a safer alternative to current treatments, with potential benefits in treating various invasive fungal infections.
FAQ
What is the current stock price of Matinas Biopharm (MTNB)?
What is the market cap of Matinas Biopharm (MTNB)?
What is Matinas BioPharma Holdings, Inc.?
What is MAT2203?
What is MAT2501?
What technology does Matinas BioPharma use?
What are the benefits of MAT2203?
What types of infections does MAT2501 target?
What is unique about Matinas BioPharma's approach?
Who can I contact for investor relations inquiries?
What is the status of MAT2203 clinical trials?
What recent achievements has Matinas BioPharma reported?
